Zurcher Kantonalbank Zurich Cantonalbank Increases Position in Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN)

Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) by 94.7% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 2,256 shares of the company’s stock after buying an additional 1,097 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Biohaven Pharmaceutical were worth $99,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in BHVN. Federated Investors Inc. PA lifted its stake in shares of Biohaven Pharmaceutical by 837.3% during the first quarter. Federated Investors Inc. PA now owns 245,758 shares of the company’s stock valued at $12,649,000 after buying an additional 219,538 shares during the period. Handelsbanken Fonder AB acquired a new position in Biohaven Pharmaceutical during the second quarter worth approximately $6,656,000. Spark Investment Management LLC increased its position in Biohaven Pharmaceutical by 312.5% during the first quarter. Spark Investment Management LLC now owns 155,100 shares of the company’s stock worth $7,982,000 after purchasing an additional 117,500 shares during the last quarter. State of New Jersey Common Pension Fund D acquired a new position in Biohaven Pharmaceutical during the first quarter worth approximately $4,375,000. Finally, C WorldWide Group Holding A S increased its position in Biohaven Pharmaceutical by 27.8% during the first quarter. C WorldWide Group Holding A S now owns 381,751 shares of the company’s stock worth $19,649,000 after purchasing an additional 83,001 shares during the last quarter. 72.33% of the stock is currently owned by institutional investors and hedge funds.

In other Biohaven Pharmaceutical news, Director John W. Childs acquired 10,000 shares of the company’s stock in a transaction dated Wednesday, June 26th. The stock was bought at an average price of $40.37 per share, with a total value of $403,700.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gregory Bailey acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The stock was acquired at an average cost of $37.65 per share, with a total value of $188,250.00. Following the transaction, the director now directly owns 2,587,601 shares of the company’s stock, valued at $97,423,177.65. The disclosure for this purchase can be found here. Insiders bought 22,500 shares of company stock valued at $900,675 in the last three months. Company insiders own 23.90% of the company’s stock.

Several equities analysts recently commented on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $84.00 price target (down previously from $89.00) on shares of Biohaven Pharmaceutical in a research report on Tuesday, June 25th. Zacks Investment Research lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, July 19th. ValuEngine lowered shares of Biohaven Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, June 19th. Morgan Stanley set a $50.00 price target on shares of Biohaven Pharmaceutical and gave the stock a “hold” rating in a research report on Friday, August 9th. Finally, Goldman Sachs Group assumed coverage on shares of Biohaven Pharmaceutical in a research report on Monday, May 6th. They set a “buy” rating and a $92.00 price target for the company. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $69.55.

Shares of Biohaven Pharmaceutical stock traded up $0.76 during trading hours on Thursday, hitting $38.18. The company’s stock had a trading volume of 20,975 shares, compared to its average volume of 682,247. Biohaven Pharmaceutical Holding Co Ltd has a 1-year low of $29.17 and a 1-year high of $67.86. The business has a fifty day moving average of $41.93 and a 200 day moving average of $50.10. The company has a market capitalization of $1.99 billion, a PE ratio of -6.19 and a beta of 0.24.

Biohaven Pharmaceutical (NYSE:BHVN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.09) by ($0.26). Analysts anticipate that Biohaven Pharmaceutical Holding Co Ltd will post -7.51 EPS for the current year.

Biohaven Pharmaceutical Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Further Reading: What is a put option?

Want to see what other hedge funds are holding BHVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN).

Institutional Ownership by Quarter for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.